Latest News - Biogen
Top Corporates Hub
Biogen
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
22.07.2026 14:00
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Profitable Stocks We Steer Clear Of
21.07.2026 12:46
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform
20.07.2026 16:15
By Daniella Parra VERAXA Biotech said it received positive scientific advice from Germany’s Paul-Ehrlich-Institute supporting a preclinical development plan for its experimental BiTAC-TCE cancer therapy platform. The feedback provides greater regulatory clarity and reduces some early-stage development risk as the company advances its lead candidate toward clinical trials, it said. READ MORE The Cancer […] The post VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform appeared first
Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch
19.07.2026 02:15
Stoke Therapeutics outlook: Phase 3 Dravet program catalysts, strong cash runway, and upside from partnerships. Click for more on STOK stock.
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead
15.07.2026 15:17
Biogen’s 14.4% return over the past six months has outpaced the S&P 500 by 6.2%, and its stock price has climbed to $192.84 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
15.07.2026 14:51
BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.
Biogen Appoints Michael J. Parini as Chief Legal Officer
15.07.2026 12:15
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve as a member of Biogen's Executive Committee and report to Christopher A. Viehbacher, President and Chief Executive Officer. In this role, Mr. Parini will have responsibility for oversight of Biogen’s global legal and compliance functions. “Michael brings to Biogen a rare combination of deep legal an
AAIC26: Biogen stock drops after unveiling tau-targeting ASO data
15.07.2026 11:25
Data released by Biogen at AAIC26 appears to have spooked investors, with an 8.17% drop in share price.
Tau In The Clinic, Again
15.07.2026 06:20
As evidence piled up that amyloid is not going to be the answer in Alzheimer's, tau has been on the upswing. Now we have another test: Diranersen, an antisense oligo from Biogen and Ionis.
Biogen (BIIB) Following Fresh Alzheimer’s Data Is The Upside Story Still Intact
15.07.2026 02:11
Biogen (BIIB) is back in focus after fresh Alzheimer’s data, including new real world results for LEQEMBI and Phase 2 findings for tau targeting candidate diranersen, gave investors more information on the company’s neurology pipeline. See our latest analysis for Biogen. Despite the positive Alzheimer’s headlines, Biogen’s 1 day share price return was down 8.17% and the 7 day share price return was down 6.68%. However, the year to date share price return of 7.95% and 1 year total shareholder...
1 Mid-Cap Stock to Target This Week and 2 We Find Risky
14.07.2026 11:03
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?
13.07.2026 06:00
Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London.
Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
09.07.2026 14:31
Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease that can affect multiple organ systems, with disease severity and clinical manifestations varying considerably among patients. Despite significant advances in understanding its pathophysiology, SLE remains incurable, and current treatment strategies primarily focus on controlling disease activity, achieving remission or low disease activity, preventing irreversible organ damage, minimizing flares, and improving patients'
Biogen's Q2 2026 Earnings: What to Expect
09.07.2026 12:28
Biogen is poised to announce its second-quarter results later this month, and analysts predict a double-digit drop in the company’s bottom-line figure.
Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right Now
05.07.2026 12:59
Biogen Inc. (NASDAQ:BIIB) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, it was reported that Biogen is scaling back Apellis Pharmaceuticals’ research pipeline and reducing its R&D staff, weeks after completing a $5.6 billion acquisition of the company. Biogen has suspended several legacy research programs, including Phase […]
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
04.07.2026 08:22
This could be a key move for future growth.
1 S&P 500 Stock with Promising Prospects and 2 We Question
02.07.2026 09:32
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Is Biogen (BIIB) Priced Near Fair Value After Its 57% Run?
02.07.2026 07:14
Biogen stock has delivered a strong 57.5% return over the past year, and with the current valuation checks painting a mixed picture rather than a clear bargain or clear overvaluation, investors are weighing how much of the recent Alzheimer’s and immunology news is already reflected in the price. Over the last 12 months, Biogen has returned 57.5%, which puts a spotlight on whether today’s share price still offers an attractive entry point or mainly reflects recent optimism. On the upside,...
Biogen (BIIB) To Share New Alzheimer’s Data At AAIC 2026
02.07.2026 01:18
Biogen (NasdaqGS:BIIB) plans to present new investigational data from its Alzheimer’s portfolio at AAIC 2026. The company will share detailed Phase 2 CELIA results for diranersen, a tau-targeting therapy. Biogen will also present real-world evidence on subcutaneous lecanemab, including usage patterns and long-term outcomes. For investors tracking Biogen, the AAIC 2026 agenda centers on two core Alzheimer’s assets that are central to the company’s neurodegeneration focus. Diranersen targets...
Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?
29.06.2026 12:07
Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.